 |
RiverVest Venture Partners® a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
Rivervest Venture Partners Announces Opening of Cleveland, OH Office and Hiring of Karen Spilizewski as Vice President -- December 17, 2007
Tryton Medical, Inc. Closes $14 Million Financing -- March 31, 2008
Luminous Medical Secures $23.5 Million -- March 18, 2008
TissueLink Medical Changes Name to Salient Surgical Technologies -- March 12, 2008
Accumetrics Accounted $28.8 Million Financing and Initiation of Pivotal Clinical Trial -- February 21, 2008
Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases -- November 27, 2007
Calypso® Medical and IMPAC Medical Systems to develop motion management solutions -- October 28, 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement -- October 18, 2007
Pediatric Asthma Programs with CyDex Captisol Technology Acquired by AstraZeneca -- October 3, 2007
TissueLink Medical Names Richard M. Altieri Vice President and Chief Financial Officer -- September 10, 2007
Aradigm and CyDex Sign Development Collaboration Agreement -- September 6, 2007
Calypso® Medical Announces Intent to Interface with Treatment Solutions from Varian Medical Systems -- July 22, 2007
MacroGenics IND for West Nile Virus Monoclonal Antibody is Active Phase 1 Clinical Trial to Commence in 2007 -- July 9, 2007
TissueLink Medical Names Joseph F. Army President and Chief Executive Officer -- June 22, 2007
CYDEX Licenses Capitisol® to Sunesis Pharmaceuticals for Oncology Drug Candidate -- May 3, 2007
XOFT Reaches Milestone as AXXENT® Electronic Brachytherapy System is Used to Treat Early Stage Breast Cancer Patients -- May 2, 2007
CyDex Licenses Captisol® to Proteolix, Inc. for Promising Oncology Compound -- May 1, 2007
Fall 2002
Spring 2003
Fall 2003
Spring 2004
Winter 2004
Summer 2005
Spring 2006
Fall 2006
Spring 2008
|
